BrightGene terminates the review of stock issuance to specific objects

Zhitong
2025.10.20 08:35

In 2025, BrightGene Bio-Medical Technology Co., Ltd. held the 13th meeting of the fourth board of directors, where it reviewed and approved the proposal to terminate the issuance of A-shares to specific targets for the year 2024 and to withdraw the application documents, with related director Yuan Jiandong abstaining from the vote. Subsequently, the company and its sponsor, Guolian Minsheng Securities Co., Ltd., submitted an application to the Shanghai Stock Exchange to withdraw the application documents and revoke the sponsorship work. On October 21, the company announced that it had previously received the Shanghai Stock Exchange's decision to terminate the review of BrightGene Bio-Medical Technology Co., Ltd.'s issuance of stocks to specific targets, based on relevant regulations

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer